SCHEMBL6017076

SCHEMBL6017076

Cc1cc(-n2c(=O)[nH]c3cc(NCc4ccc(F)cc4)ccc3c2=O)cc(C)c1NC(=O)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.56
RXFP1 Q9HBX9 3/20 0.36
MAPT P10636 4/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTR3A P46098 2/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
LMNA P02545 4/20 0.33
FBP1 P09467 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
ALDH1A1 P00352 2/20 0.32
GSAP A4D1B5 1/20 0.32
HTT P42858 1/20 0.32
GALR3 O60755 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094405 0.92 P2RY12 (0.59) P2RY12RXFP1MAPTTP53POLB
SCHEMBL13635114 0.91 P2RY12 (0.66) P2RY12RXFP1MAPTTP53POLB
SCHEMBL4425407 0.87 P2RY12 (0.51) P2RY12RXFP1MAPTTP53POLB
SCHEMBL13634811 0.87 P2RY12 (0.66) P2RY12RXFP1MAPTTP53POLB
SCHEMBL13635262 0.86 P2RY12 (0.64) P2RY12RXFP1MAPTTP53MEN1
SCHEMBL13635083 0.86 P2RY12 (0.66) P2RY12RXFP1MAPTTP53MEN1
SCHEMBL4412718 0.85 P2RY12 (0.54) P2RY12RXFP1MAPTTP53MEN1
SCHEMBL4418832 0.85 P2RY12 (0.54) P2RY12RXFP1MAPTTP53POLB
SCHEMBL13635281 0.85 P2RY12 (0.68) P2RY12RXFP1MAPTTP53POLB
SCHEMBL13635072 0.85 P2RY12 (0.64) P2RY12RXFP1MAPTTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-A4 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2006-12-20 EP disclosed
US-7109332-B2 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1668002-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS Portola Pharmaceuticals, Inc. (US) 2006-06-14 EP disclosed
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed
WO-2005032488-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARMACEUTICALS, INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PFKP, DPP3, P2RY13 P2RY12 21/4885RXFP1 2023/4885MAPT 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.